We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A scientist holding a vial containing a liquid with a DNA helix design, symbolizing the drug manufacturing process and biotechnology.
Product News

LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities

LGM Pharma announces a $6M investment to expand its Rosenberg, Texas facility, enhancing its capacity for liquid, semi-solid and suppository drug production. The expansion supports growing prescription drug demand.
A scientist in a laboratory examining a sample, representing bioprocessing research and biotechnology innovation.
Product News

BIOVECTRA Is Honored With 2025 CDMO Leadership Award for Biologics

BIOVECTRA, part of Agilent Technologies, has been awarded the 2025 Outsourced Pharma CDMO Leadership Award in biologics for its exceptional quality, reliability and technical capability.
Scientists in a biopharma laboratory conducting research, analyzing samples, and using advanced equipment.
Product News

Thermo Fisher Scientific Introduces TSX™ Core Series ULT Freezers

Thermo Fisher Scientific introduces the Thermo Scientific™ TSX™ Core Series ULT freezers, designed to provide reliable performance and robust durability in a user-friendly solution.
A scientist.
Product News

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company, announced the successful completion of a sprint project to deliver clinical material.
Mechanism of Action of LEN.
Product News

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools To Outsmart HIV

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).
Antibodies.
Product News

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement With LINDIS Biotech for the Commercial Supply of Catumaxomab

Celonic Group, a “Pure Play” biologics contract development and manufacturing organization (CDMO), announced the signing of a multi-year commercial manufacturing agreement with LINDIS Biotech.
Advertisement